Sung Won Lee

Sung Won Lee

Auto-generated profile, based on publicly available information

Sung Won Lee

Division of Rheumatology, Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SPSo Youn Park
So Youn Park
SLSung Won Lee
Sung Won Lee
HSHwa-Kyoung Shin
Hwa-Kyoung Shin
WCWon Tae Chung
Won Tae Chung
Won Suk LeeWon Suk Lee
Won Suk Lee
CKChi Dae Kim
Chi Dae Kim
Objective: To assess the effects of cilostazol in inhibiting proliferation and enhancing apoptosis in synovial cells from patients with rheumatoid arthritis (RA).Methods: Synovial cell proliferation was measured by MTT assay. The expression of NF‐κB, IκBα, Bcl‐2, Bax, heme oxygenase 1 (HO‐1), and Nrf2 was determined by Western blotting.Results: Cilostazol suppressed synovial cell proliferation by arresting the G2/M phases of the cell cycle, and this was reversed by KT5720, an inhibitor of protein kinase A. Cilostazol increased the number of TUNEL‐positive cells, with increased cytochrome c release and apoptosis‐inducing factor translocation as well as increased caspase 3 activation. Cilostazol (10 μM) and cobalt protoporphyrin IX (CoPP) increased HO‐1 messenger RNA and protein expression. These effects were suppressed by zinc protoporphyrin IX (ZnPP), an HO‐1 inhibitor. Cilostazol and CoPP significantly increased IκBα in the cytosol and decreased NF‐κB p65 expression in the nucleus. Increased expression of tumor necrosis factor α (TNFα), interleukin‐1β (IL‐1β), and IL‐6 induced by lipopolysaccharide was attenuated by cilostazol and CoPP, and this was reversed by ZnPP. In mice with collagen‐induced arthritis treated with cilostazol (10 and 30 mg/kg/day), paw thickness was decreased with increased apoptotic cells in the joints. In synovial cells transfected with small interfering RNA (siRNA) targeting HO‐1, cilostazol did not suppress expression of TNFα, IL‐1β, and IL‐6, in contrast to findings with negative control cells. Cilostazol‐ and CoPP‐induced HO‐1 expression was diminished in cells transfected with Nrf2 siRNA.Conclusion: Cilostazol suppressed proliferation of synovial cells from RA patients by enhancing apoptosis, and also inhibited cytokine production via mediation of cAMP‐dependent protein kinase activation–coupled Nrf2‐linked HO‐1 expression.

9 October 2009 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
SLSung-Won Lee
Sung-Won Lee
SLSang-Yeob Lee
Sang-Yeob Lee
KKKi-Nam Kim
Ki-Nam Kim
JJJin-Kyu Jung
Jin-Kyu Jung
WCWon-Tae Chung
Won-Tae Chung

11 September 2019 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
SLSung Won Lee
Sung Won Lee
SKSeong-Yong Kim
Seong-Yong Kim
SCSung Hae Chang
Sung Hae Chang
Background: We aimed to evaluate the prevalence of foot and/or ankle arthritis (FAA) and its impact on clinical indices in patients with rheumatoid arthritis (RA). Methods: This cross-sectional study used data from the Korean College of Rheumatology Biologics & Targeted therapy registry to observe clinical outcomes of patients undergoing biologics therapy and conventional therapy. FAA was defined as ≥1 tender or swollen joint in the ankle and/or 1st-5th metatarsophalangeal (MTP) joints. Disease Activity Score 28 (DAS28), Routine Assessment of Patient Index Data 3 (RAPID3), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) were assessed. Results: Among 2046 patients, 598 had FAA. The ankle joint was the most commonly involved joint in FAA (tender joint, 71.4%; swollen joint, 59.5%), followed by the third and second MTP joints. Patients with FAA showed higher DAS28, RAPID3, SDAI, and CDAI scores. FAA presence was significantly associated with non-remission as per DAS28-ESR (odds ratio, 3.4; 95% confidence interval, 2.0–5.8), DAS28-CRP (3.6, 2.4–5.3), SDAI (6.3, 2.8–14.6), CDAI (7.6, 2.4–24.3), and RAPID3 (5.6, 2.7–11.5) indices on adjusting for age, sex, disease duration, presence of rheumatoid factor, presence of anti-cyclic citrullinated peptide antibody, lung disease, use of methotrexate, and previous use of biological disease-modifying anti-rheumatic drugs. Patients with FAA were less likely to achieve remission of SDAI (n = 6, 1.0%) and CDAI (n = 3, 0.5%) than that of DAS28-ESR (n = 21, 3.5%), DAS28-CRP (n = 38, 6.4%), and RAPID3 (n = 12, 2.0%). Conclusions: FAA represents a severe disease activity and is an independent risk factor for non-remission in patients with RA.

1 December 2015 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
SLS.W. Lee
S.W. Lee
JRJ.H. Rho
J.H. Rho
SLSang Yeob Lee
Sang Yeob Lee
JKJ.H. Kim
J.H. Kim
JCJaeHun Cheong
JaeHun Cheong
YYYoung Hyun Yoo
Young Hyun Yoo


1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SLSung Won Lee
Sung Won Lee
SLShin-Seok Lee
Shin-Seok Lee
DODong Ho Oh
Dong Ho Oh
DPDong-Jin Park
Dong-Jin Park
HKHyun-Sook Kim
Hyun-Sook Kim
SKSeong-Kyu Kim
Seong-Kyu Kim
Lee SW, et al. J Korean Med Sci. 2016 Oct;31(10):1566-1570. https://doi.org/10.3346/jkms.2016.31.10.1566